TY - JOUR T1 - Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark JF - medRxiv DO - 10.1101/2021.05.07.21256725 SP - 2021.05.07.21256725 AU - Kamille Fogh AU - Alexandra RR Eriksen AU - Rasmus B Hasselbalch AU - Emilie Sofie Kristensen AU - Henning Bundgaard AU - Susanne D Nielsen AU - Charlotte S Jørgensen AU - Bibi FSS Scharff AU - Christian Erikstrup AU - Susanne G Sækmose AU - Dorte K Holm AU - Bitten Aagaard AU - Jakob Norsk AU - Pernille Brok Nielsen AU - Jonas H Kristensen AU - Lars Østergaard AU - Svend Ellermann-Eriksen AU - Berit Andersen AU - Henrik Nielsen AU - Isik S Johansen AU - Lothar Wiese AU - Lone Simonsen AU - Thea K. Fischer AU - Fredrik Folke AU - Freddy Lippert AU - Sisse R Ostrowski AU - Steen Ethelberg AU - Anders Koch AU - Anne-Marie Vangsted AU - Tyra Grove Krause AU - Anders Fomsgaard AU - Claus Nielsen AU - Henrik Ullum AU - Robert Skov AU - Kasper Iversen Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/10/2021.05.07.21256725.abstract N2 - Background COVID-19 is suggested to be more prevalent among ethnic minorities and individuals with low socioeconomic status. We aimed to investigate the prevalence of SARS-CoV-2 antibodies during the COVID-19 pandemic among citizens 15 years or older in Denmark living in social housing (SH) areas.Methods As part of “Testing Denmark”, a nationwide sero-epidemiological surveillance survey, we conducted a study between January 8th and January 31st, 2021 with recruitment in 13 selected SH areas in Denmark. Participants were offered a point-of-care rapid SARS-CoV-2 IgM and IgG antibody test and a questionnaire concerning previous testing (viral throat- and nasopharyngeal swab or antibody test), test results for COVID-19, demographics, household characteristics, employment, risk factors for SARS-CoV-2 infection and history of symptoms associated with COVID-19. Data on seroprevalence from Danish blood donors in same period using a total Ig ELISA assay were used as a proxy for the general Danish population.Findings Of the 13,279 included participants, 2,296 (17.3%) were seropositive (mean age 46.6 (SD 16.4) years, 54.2% female), which was 3 times higher than in the general Danish population (mean age 41.7 (SD 14.1) years, 48.5% female) in the same period (5.8%, risk ratios (RR) 2.96, 95% CI 2.78-3.16, p>0.001). Seropositivity was higher among males than females (RR 1.1, 95% CI 1.05-1.22%, p=0.001) and increased with age, with an OR seropositivity of 1.03 for each 10-year increase in age (95% CI 1.00-1.06, p=0.031). Close contact with COVID-19-infected individuals was associated with a higher risk of infection, especially among members of the same households (OR 5.0, 95% CI 4.1-6.2 p<0,001). Adjusted for age, gender and region living at least 4 people in a household significantly increased the OR of seropositivity (OR 1.3, 95% CI 1.1-1.6, p=0.02) as did living in a multi-generational household (OR 1.3 per generation, 95% CI 1.1-1.5, p=0.007). Only 1.6% of participants reported not following any of the national COVID-19 recommendations. Anosmia (RR 3.2 95% CI 2.8-3.7, p<0.001) and ageusia (RR 3.3, 95% CI 2.9-3.8, p<0.001) were strongest associated with seropositivity.Interpretation Danish citizens living in SH areas of low socioeconomic status had a three times higher SARS-CoV-2 seroprevalence compared to the general Danish population. The seroprevalence was significantly higher in males and increased with age. Living in multiple generations or more than four persons in a household was an independent risk factor for being seropositive. Results of this study can be used for future consideration of the need for preventive measures in the populations living in SH areas.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from the foundations of Trygfonden and Helsefonden. The funders did not influence study design, conducting or reporting.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was performed as a national cross-sectional surveillance study under the authority task of Statens Serum Institut (SSI, Copenhagen, Denmark; which performs the epidemiological surveillance of infectious diseases for the Danish government) and according to Danish law does not require any formal approval from an ethics committee. This was in accordance with the regional ethics committee from the Capital region in Denmark (20057075), who made the above determination that the study did not require approval from an ethics committee. The study was performed in agreement with the Helsinki II declaration and registered with the Danish Data protection Authorities (P-2020-901). Participation was voluntary. All personal data obtained in REDCap was kept in accordance with the general data protection regulation and data protection law stated by the Danish Data Protection Agency.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll personal data obtained in REDCap was kept in accordance with the general data protection regulation and data protection law stated by the Danish Data Protection Agency. ER -